Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.
No articles found.
Systec & Solutions GmbH, with headquarters in Karlsruhe (Germany), is a specialize...
Systec & Solutions GmbH, with headquarters in K...
Since the companyâs inception, Tetraphase has developed a robust antibiotics pla...
Since the companyâs inception, Tetraphase has...
Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet...
Theratechnologies (TSX: TH) is a specialty phar...
Adamas Pharmaceuticals, Inc. is using its deep understanding of time-dependent bio...
Adamas Pharmaceuticals, Inc. is using its deep ...
Vir integrates diverse innovations in science, technology, and medicine to transfo...
Vir integrates diverse innovations in science, ...
Savara is an orphan lung disease company. Savaraâs pipeline comprises Molgradex,...
Savara is an orphan lung disease company. Savar...
NextCure is a clinical-stage biopharmaceutical company committed to discovering an...
NextCure is a clinical-stage biopharmaceutical ...
The discovery of immunosuppressive (anti-rejection) drugs has made possible life-s...
The discovery of immunosuppressive (anti-reject...
Join the National Investor Network and get the latest information with your interests in mind.